Shots:
- The US FDA has approved Abbott’s Portico with FlexNav TAVR system to treat patients with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery. The system provides a safe & effective treatment option
- Abbott’s Portico is a self-expanding TAVR valve with an intra-annular leaflet that is designed to provide optimal blood flow when placed inside a patient’s natural valve
- Portico device is implanted using Abbott’s FlexNav delivery system to accommodate different patient anatomies, small vessels, flexibility, tracking & precision of valve placement. Abbott offers a robust portfolio of structural heart solutions in the US including minimally invasive therapies
Click here to read full press release/ article | Ref: Abbott | Image: Media Post
The post Abbott’s Portico with Flexnav Tavr System Receives the US FDA’s Approval for the Treatment of Aortic Valve Disease first appeared on PharmaShots.
